FDA Approves Ribociclib, Expands Palbociclib Approval for Metastatic Breast Cancer

The FDA has approved a new targeted therapy, ribociclib, and expanded its earlier approval of another targeted therapy, palbociclib, for some women with metastatic breast cancer.

Cancer Currents: An NCI Cancer Research Blog